Merck (MRK) Cash from Discontinued Operations (2020 - 2021)

Merck (MRK) reported Cash from Discontinued Operations of 702000000.0 for Q4 2021, down 236.31% year-over-year from 515000000.0 in Q4 2020, and down 210.03% quarter-over-quarter from 638000000.0 in Q3 2021.

Merck (MRK) Cash from Discontinued Operations (2020 - 2021) Analysis & Trends

Merck (MRK) has 2 years of Cash from Discontinued Operations data on file, last reported at 702000000.0 in Q4 2021.

  • Cash from Discontinued Operations for Q4 2021 came in at 702000000.0, down 236.31% year-over-year; the trailing twelve-month figure through Sep 2022 was 702000000.0 (down 144.83% YoY), and the FY2021 annual result was 349000000.0, down 85.37% from the prior year.
  • Cash from Discontinued Operations declined to 702000000.0 in Q4 2021 per MRK's latest filing, from 638000000.0 in the prior quarter.
  • Over five years, Cash from Discontinued Operations peaked at 638000000.0 in Q3 2021 and troughed at 702000000.0 in Q4 2021.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Discontinued Operations (Qtr)
1 Gsk 92,316,836.42 Bn 92,316,831.46 Bn 7.76 Bn 1.54 Bn
2 Eli Lilly 983.57 Bn 978.29 Bn 16.22 Bn -
3 Johnson & Johnson 553.56 Bn 531.50 Bn 15.96 Bn -
4 AbbVie 383.35 Bn 374.00 Bn 10.78 Bn -
5 Merck 281.71 Bn 276.06 Bn 12.09 Bn -
6 Amgen 182.20 Bn 170.16 Bn 5.87 Bn -
7 Gilead Sciences 153.71 Bn 145.98 Bn 5.52 Bn -
8 Pfizer 143.75 Bn 130.98 Bn -1.21 Bn -
9 Bristol Myers Squibb 109.71 Bn 99.25 Bn 8.07 Bn -
10 Novartis Ag 108.28 Bn 107.60 Bn - -

Historic Data

Download Data
DateValue
Dec 31, 2021 -702.00 Mn
Dec 31, 2021 -702.00 Mn
Sep 30, 2021 638.00 Mn
Sep 30, 2021 638.00 Mn
Jun 30, 2021 -86.00 Mn
Jun 30, 2021 -86.00 Mn
Mar 31, 2021 499.00 Mn
Mar 31, 2021 499.00 Mn
Dec 31, 2020 515.00 Mn
Dec 31, 2020 515.00 Mn
Sep 30, 2020 522.00 Mn
Sep 30, 2020 522.00 Mn